SEC Comment Letter 0000000000-24-009799 to Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Date: Aug. 28, 2024 · CIK: 0001651407 · Accession: 0000000000-24-009799
AI Filing Summary & Sentiment
File numbers found in text: 333-281650
Letter
August 28, 2024 James Oliviero Chief Executive Officer Checkpoint Therapeutics, Inc. 95 Sawyer Road, Suite 110 Waltham, MA 02453 Re:Checkpoint Therapeutics, Inc. Registration Statement on Form S-3 Filed August 19, 2024 File No. 333-281650 Dear James Oliviero: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Matthew Mamak
Show Raw Text
August 28, 2024
James Oliviero
Chief Executive Officer
Checkpoint Therapeutics, Inc.
95 Sawyer Road, Suite 110
Waltham, MA 02453
Re:Checkpoint Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 19, 2024
File No. 333-281650
Dear James Oliviero:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Matthew Mamak